Edition:
United States

Flexion Therapeutics Inc (FLXN.OQ)

FLXN.OQ on NASDAQ Stock Exchange Global Market

25.26USD
23 Feb 2018
Change (% chg)

$1.07 (+4.42%)
Prev Close
$24.19
Open
$24.38
Day's High
$25.27
Day's Low
$23.96
Volume
267,189
Avg. Vol
346,980
52-wk High
$32.22
52-wk Low
$16.51

Latest Key Developments (Source: Significant Developments)

Flexion Therapeutics Acquires Rights To Genequine Biotherapeutics' Non-Opioid Drug
Wednesday, 13 Dec 2017 04:05pm EST 

Dec 13 (Reuters) - Flexion Therapeutics Inc ::FLEXION THERAPEUTICS ANNOUNCES ACQUISITION OF NOVEL, NON-OPIOID ASSET FOR OSTEOARTHRITIS OF THE KNEE.FLEXION THERAPEUTICS INC - ENTERED INTO A DEFINITIVE AGREEMENT WITH GENEQUINE BIOTHERAPEUTICS GMBH TO ACQUIRE GLOBAL RIGHTS TO GQ-20.FLEXION THERAPEUTICS - CO OBTAINED EXCLUSIVE LICENSE TO UNDERLYING INTELLECTUAL PROPERTY RIGHTS FOR HUMAN USE OF GQ-203 FROM BAYLOR COLLEGE OF MEDICINE.FLEXION THERAPEUTICS - CO TO MAKE UPFRONT PAYMENT OF $2 MILLION TO GENEQUINE & MAY INCUR MILESTONE PAYMENTS OF UP TO $8.7 MILLION THROUGH PHASE 2 POC.  Full Article

Flexion therapeutics reports third-quarter results
Monday, 6 Nov 2017 04:05pm EST 

Nov 6 (Reuters) - Flexion Therapeutics Inc :Flexion Therapeutics reports third-quarter 2017 financial results and recent business highlights.Flexion Therapeutics Inc - qtrly basic and diluted net loss per share $1.07‍​.  Full Article

Flexion Therapeutics announces pricing of public offering of common stock
Wednesday, 11 Oct 2017 05:55pm EDT 

Oct 11 (Reuters) - Flexion Therapeutics Inc :Flexion Therapeutics announces pricing of public offering of common stock.Says public offering of 4.80 million common shares priced at $25.50per share.  Full Article

Flexion Therapeutics- Proposed public offering of 4 mln common shares
Tuesday, 10 Oct 2017 04:05pm EDT 

Oct 10 (Reuters) - Flexion Therapeutics Inc :Flexion Therapeutics announces proposed public offering of common stock.Says offering 4.00 million common shares.Flexion Therapeutics Inc - Flexion intends to use net proceeds from offering to fund manufacturing and commercialization of Zilretta(TM)​.  Full Article

Flexion Therapeutics says co sent a notice of termination to Astrazeneca AB regarding an out-license agreement between parties​
Thursday, 14 Sep 2017 04:48pm EDT 

Sept 15 (Reuters) - Flexion Therapeutics Inc :Flexion Therapeutics Inc - ‍on September 8, co sent a notice of termination to Astrazeneca AB regarding an out-license agreement between parties​.Flexion Therapeutics Inc - ‍out-license agreement related to co's FX005 sustained-release p38 MAP.Flexion Therapeutics Inc - ‍pursuant to terms of out-license agreement, termination will be effective three months after company's delivery of notice​.Flexion Therapeutics Inc - ‍upon termination of out-license agreement, Flexion's license rights pertaining to FX005 will revert to Astrazeneca​.Flexion Therapeutics Inc - ‍upon termination of out-license agreement Flexion's milestone, royalty and patent maintenance obligations under agreement will cease.​.  Full Article

Flexion Therapeutics qtrly loss per share $0.91
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Flexion Therapeutics Inc :Flexion therapeutics reports second quarter 2017 financial results and recent business highlights.Flexion therapeutics inc qtrly loss per share $0.91.  Full Article

Flexion Therapeutics qtrly loss per share $0.75
Thursday, 4 May 2017 04:01pm EDT 

May 4 (Reuters) - Flexion Therapeutics Inc ::Flexion Therapeutics reports first quarter 2017 financial results and recent business highlights.Qtrly loss per share $0.75.  Full Article

Flexion Therapeutics announces pricing of $175 mln of senior notes
Wednesday, 26 Apr 2017 07:04pm EDT 

April 26 (Reuters) - Flexion Therapeutics Inc :Flexion Therapeutics announces pricing of $175 million 3.375% convertible senior notes due 2024.Size of offering was increased by $50 million from previously announced offering size of $125 million.  Full Article

Flexion Therapeutics announces proposed convertible senior notes offering
Tuesday, 25 Apr 2017 04:01pm EDT 

April 25 (Reuters) - Flexion Therapeutics Inc :Flexion Therapeutics announces proposed convertible senior notes offering.Says to offer $125 million principal amount of convertible senior notes due 2024 in a private offering.Says to use net proceeds from notes offering for commercialization and manufacture of zilretta.  Full Article

Flexion reports year-end 2016 financial results
Thursday, 9 Mar 2017 04:01pm EST 

Flexion Therapeutics Inc : Flexion reports year-end 2016 financial results . Frederick Driscoll, chief financial officer, intends to retire effective March 31, 2017 . Driscoll will continue with company in an advisory capacity until his successor has been named .Commercialization plans on target for potential Q4 launch of zilretta.  Full Article

BRIEF-Flexion Therapeutics Announces Initial Data From Clinical Trial Evaluating Repeat Administration Of Zilretta

* FLEXION THERAPEUTICS ANNOUNCES INITIAL DATA FROM CLINICAL TRIAL EVALUATING REPEAT ADMINISTRATION OF ZILRETTA™ (TRIAMCINOLONE ACETONIDE EXTENDED-RELEASE INJECTABLE SUSPENSION)